[go: up one dir, main page]

WO2008043024A3 - Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease - Google Patents

Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease Download PDF

Info

Publication number
WO2008043024A3
WO2008043024A3 PCT/US2007/080454 US2007080454W WO2008043024A3 WO 2008043024 A3 WO2008043024 A3 WO 2008043024A3 US 2007080454 W US2007080454 W US 2007080454W WO 2008043024 A3 WO2008043024 A3 WO 2008043024A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfonyl
treatment
oral pharmaceutical
ppar
bicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/080454
Other languages
French (fr)
Other versions
WO2008043024A2 (en
Inventor
James L Gallagher
Robyn A Rourick
Shawn A Scranton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalypsys Inc
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of WO2008043024A2 publication Critical patent/WO2008043024A2/en
Publication of WO2008043024A3 publication Critical patent/WO2008043024A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Provided herein are oral pharmaceutical formulations of 4-[cis-2,6-dimethyl-4- (4-trifluoromethoxy-phenyl)-piperazine- 1 -sulfonyl]-indan-2-carboxylic acid which may be useful as inhibitors of peroxisome proliferator activated receptors (PPARs) for the treatment or prevention of diseases such as diabetes, hyperglycemia, metabolic syndrome, obesity, or atherosclerosis.
PCT/US2007/080454 2006-10-04 2007-10-04 Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease Ceased WO2008043024A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84931006P 2006-10-04 2006-10-04
US60/849,310 2006-10-04

Publications (2)

Publication Number Publication Date
WO2008043024A2 WO2008043024A2 (en) 2008-04-10
WO2008043024A3 true WO2008043024A3 (en) 2008-09-18

Family

ID=38895884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/080454 Ceased WO2008043024A2 (en) 2006-10-04 2007-10-04 Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease

Country Status (1)

Country Link
WO (1) WO2008043024A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR052319A1 (en) 2004-10-29 2007-03-14 Kalypsys Inc BICYCLIC COMPOUNDS REPLACED BY SULFONYL IN FUNCTION OF PPAR MODULATORS
BRPI0619282B8 (en) 2005-10-25 2021-05-25 Kalypsys Inc salt, and pharmaceutical composition
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) * 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EP3600314A1 (en) 2017-03-27 2020-02-05 Tesaro, Inc. Niraparib compositions
US11730725B2 (en) * 2017-09-26 2023-08-22 Tesaro, Inc. Niraparib formulations
JP2023505687A (en) 2019-12-11 2023-02-10 インスピルナ，インコーポレーテッド Cancer treatment method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092117A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
WO2005016881A1 (en) * 2003-08-02 2005-02-24 Bayer Healthcare Ag Bicyclic indoline sulfonamide derivatives
US20060167012A1 (en) * 2004-10-29 2006-07-27 Noble Stewart A Sulfonyl-substituted bicyclic compounds as modulators of PPAR

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092117A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
WO2005016881A1 (en) * 2003-08-02 2005-02-24 Bayer Healthcare Ag Bicyclic indoline sulfonamide derivatives
US20060167012A1 (en) * 2004-10-29 2006-07-27 Noble Stewart A Sulfonyl-substituted bicyclic compounds as modulators of PPAR

Also Published As

Publication number Publication date
WO2008043024A2 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
WO2008043024A3 (en) Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
RU2462456C2 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
NO20091700L (en) Florizine analogues as inhibitors of glucose co-transporter 2
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
IL213806A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
LTC1793824I2 (en) New pharmaceutical compositions comprising 4- (4- (3- (4-chloro-3-trifluoromethylphenyl) ureido) -3-fluorophenoxy) pyridine-2-carboxylic acid for the treatment of hyperproliferative disorders
WO2007104789A3 (en) Amylin derivatives
WO2008005569A3 (en) Modulators of metabolism and the treatment of disorders related thereto
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
EA200970090A1 (en) METABOLISM MODULATORS AND TREATMENT OF RELATED DISORDERS
TW200745052A (en) Thyroid hormone receptor agonists
CA2725933A1 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
WO2008020040A3 (en) 2,5-dihydroxybenzene compounds for the treatment of fibrosis
WO2007065808A3 (en) Neuropeptide-2 receptor-agonists
IL181009A0 (en) N-(phenyl-oxazol-4-ylmethoxymethyl)-cyclohexyl-succinic acid amide derivatives and related compounds which are used as ppar-ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes
ATE554084T1 (en) N-HYDROXYACRYLAMIDE COMPOUNDS
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
WO2007056771A3 (en) Compounds for the treatment of metabolic disorders
NO20054396L (en) 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy) -cyclohexanecarbonylamino) -morbic acid derivatives and similar compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis
WO2005058824A3 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprote in b
WO2007124869A3 (en) Liquid pharmaceutical formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843845

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07843845

Country of ref document: EP

Kind code of ref document: A2